New review proposes gene-edited Beagles as a complementary model for autism research

More than 90 percent of autism drugs fail in trials, and a new review argues dogs bred to read human faces could be the missing test model.



Evaluation of potential drugs in autism-associated Shank3 mutant dogs.

WUHAN, HUBEI, CHINA, June 24, 2026 /EINPresswire.com/ -- For thirty years the search for autism medicines has hit the same wall, and a new peer-reviewed Perspective in Genomic Psychiatry suggests that the way around it has been sleeping at our feet the entire time. The article is a synthesis rather than a fresh experiment. It gathers a decade of scattered findings and makes a quiet, provocative case. The laboratory Beagle, that gentle and biddable companion, may be the missing bridge between the petri dish and the clinic.

> The dog brings the social dimension of autism into focus in a way other models cannot; it is a third lens on the very biology of human connection."
>
> *Dr. Yong Q. Zhang, School of Life Sciences, Hubei University*

The old models keep failing for a reason the review traces to a single cause. More than ninety percent of candidate autism drugs collapse somewhere between the laboratory and the human trial. The animals we test on cannot do the one thing autism most disturbs, which is to be social in the rich, glancing, eye-meeting way that people are. Mice are convenient and genetically pliable, yet a mouse does not read a face. Monkeys come closer, but they breed slowly, cost a great deal to keep, and, the authors note, a steady human gaze reads to a macaque not as warmth but as threat. If a drug cannot mend sociability in a creature that was never very social to begin with, how would anyone know whether it works? The question the synthesis poses is plain. What if the better model has been bred, over thirty thousand years, to look back at us?

"Dogs did not simply move in beside us. They co-evolved to understand us," said Dr. Siqi Yuan, lead author of the Perspective. "That shared social wiring is exactly what other laboratory species lack, and it is exactly what autism research has been missing."



gp.genomicpress.com

Genomic Psychiatry

OPEN

PERSPECTIVE

Emerging gene-edited dog models for autism spectrum disorder

Siqi Yuan[1,2,3,#], Qi Shi[1], Hui Zhao[4], Kun Guo[5], Yong-hui Jiang[6], and Yong Q. Zhang[1]

The translational failure rate of drug development for autism spectrum disorder (ASD) exceeds 90% in human clinical trials, largely attributable to inadequate animal models that cannot capture human sociocognitive complexity. Although nonhuman primates offer a higher translational potential for ASD, they remain underexplored. We propose that the laboratory Beagle dog is an ideal alternative model for ASD due to species-specific traits: highly developed social and cognitive abilities, brain structure and function similar to that of humans, and ease of training and obedience. Moreover, advanced genome-editing technologies have enabled the generation of large animal models with specific mutations in high-risk ASD genes such as *Shank3*; mutations in its human homologue are the most replicated and characterized in idiopathic ASD. Here, we focus on CRISPR/Cas9-generated *Shank3* mutant dogs, which recapitulate ASD-like symptoms, including social deficits and sensory processing abnormalities, as well as face cognition impairment. Importantly, some of these abnormalities can be ameliorated by various reagents such as oxytocin, psychedelics, or the $GABA_A$ receptor antagonist pentylenetetrazol (PTZ). These findings highlight the potential of dog models to bridge the gap between basic research and clinical translation, and offer new experimental systems for testing and evaluating candidate ASD therapies.

Genomic Psychiatry (2026), 1–7; doi: https://doi.org/10.61373/gp026p.0036

Keywords: Autism, dog model, drug development, gene-editing, *Shank3*

Emerging gene-edited dog models for autism spectrum disorder

What the synthesis pulls together centers on a line of dogs carrying engineered changes in Shank3, a gene whose human counterpart is among the most reliably linked to autism. Across the studies the authors review, these dogs reproduce a striking range of human traits. They withdraw from social contact. They show altered responses to sound, to touch, and to pain. They look away from the eyes of a human face more quickly than other dogs do, the very flinch from the gaze that clinicians observe in autistic people. The review draws these threads into a single table of parallels, from synapse to behavior, that no individual study had assembled before. What does it mean that a dog, given the human version of an autism gene, begins to behave in human ways?

“When you place the canine findings beside the human literature, the overlaps are difficult to dismiss,” said Professor Yong Q. Zhang, the corresponding author, of the School of Life Sciences at Hubei University.

Glimmers of treatment surface in the synthesis, though the authors hold them firmly at arm's length. The review gathers early and frankly preliminary signs that some of these traits can be eased. Oxytocin, a bonding hormone delivered here as a nasal spray, lengthened the time mutant mothers spent licking their pups and coaxed the dogs to dwell longer on the human eye region. A carefully dosed psychedelic restored a kind of brain-to-brain synchrony between dog and handler that the mutation had broken. A compound that nudges neural activity back toward excitation rescued blunted touch sensitivity and social interaction. Could these scattered rescues point toward medicines that help people? The authors are careful. The samples are small, the settings controlled, and the human record on oxytocin remains mixed. Promise is not proof.

The synthesis offers an honest reckoning with the discomfort the work provokes, and the authors do not pretend otherwise. Dogs occupy a tender place in human life, and the use of them in research troubles many people deeply. The review meets that discomfort head on. It binds the work to the principles known as the three Rs, replacement, reduction, and refinement, and stresses that every study passes stringent ethical review designed to use as few animals as possible. There is a hard tension here, named plainly in the paper. Too few animals and the data crumble. Too many and the moral cost climbs. Striking that balance, the authors write, is the difficult center of the whole enterprise. Is it possible that the animal we domesticated for companionship is, all along, the one best suited to study the biology of connection?

The road ahead is soberly mapped, and other limits are technical. Gene editing in dogs still succeeds only about a quarter of the time. Some mutations prove lethal. Training a dog to lie still for a brain scan can take the better part of two years. And the toolkit for canine neuroscience remains thin beside the lavish one built for mice. Where, then, does the field go? The authors call for new cross-disciplinary collaborations, improved editing methods, and gentler training approaches. Their closing argument is modest and, in its way, moving. The dog earns its place in this work not as a tool but as a translator, an animal that has spent thirty thousand years learning to read us, now asked to help us read ourselves.

The peer-reviewed Perspective in Genomic Psychiatry titled “Emerging gene-edited dog models for autism spectrum disorder” is freely available via Open Access, starting on 24 June 2026 in Genomic Psychiatry at the following hyperlink: https://doi.org/10.61373/gp026p.0036.

The full reference for citation purposes is: Yuan S, Shi Q, Zhao H, Guo K, Jiang Y-H, Zhang YQ. Emerging gene-edited dog models for autism spectrum disorder. Genomic Psychiatry 2026. DOI: https://doi.org/10.61373/gp026p.0036. Epub 2026 Jun 24.

About Genomic Psychiatry: Genomic Psychiatry: Advancing Science from Genes to Society (ISSN: 2997-2388, online and 2997-254X, print) represents a paradigm shift in genetics journals by interweaving advances in genomics and genetics with progress in all other areas of contemporary psychiatry. Genomic Psychiatry publishes peer-reviewed medical research articles of the highest quality from any area within the continuum that goes from genes and molecules to neuroscience, clinical psychiatry, and public health.

Visit the Genomic Press Virtual Library: https://issues.genomicpress.com/bookcase/gtvov/

Our media website is at: https://media.genomicpress.com/

Our full website is at: https://genomicpress.com/

Ma-Li Wong
Genomic Press
mali.wong@genomicpress.com
Visit us on social media:
X
LinkedIn
Bluesky
Instagram
Facebook

---

we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.